What is a multidisciplinary tumor board and should my Colorectal Cancer case be presented

Understanding Multidisciplinary Tumor Boards for Colorectal Cancer

What Is a Multidisciplinary Tumor Board?

A multidisciplinary tumor board (often called a "tumor conference" or "case conference") is a team meeting where different cancer specialists review your case together and discuss the best treatment approach. Think of it as bringing together all the experts who might be involved in your care to look at your situation from multiple angles.

Who typically participates:

• Medical oncologists (chemotherapy specialists)
• Surgical oncologists (cancer surgeons)
• Radiation oncologists (radiation therapy specialists)
• Radiologists (imaging specialists who interpret scans)
• Pathologists (specialists who examine tissue samples)
• Gastroenterologists (digestive system specialists)
• Nurses and other support staff

Why This Matters for Colorectal Cancer

According to the NCCN Guidelines for Colon Cancer (Version 5.2025), the Panel explicitly states: "A multidisciplinary approach is necessary for managing CRC" (colorectal cancer). This isn't optional—it's considered a core principle of good cancer care.

The guidelines emphasize that treatment recommendations can vary considerably based on:

• Your cancer stage
• Biomarker results (like MSI/MMR status, KRAS, BRAF mutations)
• Whether your cancer is resectable (can be surgically removed)
• Whether you have metastatic disease (cancer spread to other organs)

Should Your Case Be Presented?

Yes—your colorectal cancer case should ideally be presented to a multidisciplinary tumor board, especially if:

✅ You have newly diagnosed colon cancer requiring surgery planning ✅ Your cancer is locally advanced (T4b tumors or bulky lymph node involvement) ✅ You have metastatic disease (cancer in liver, lungs, or other organs) ✅ Your case is complex or doesn't fit standard treatment patterns ✅ You're considering clinical trials or novel treatment combinations ✅ Your biomarker testing shows specific mutations (BRAF, KRAS, MSI-H/dMMR, HER2 amplification) ✅ You've had treatment failure or recurrence

What Happens at Tumor Board Review

The team will typically discuss:

1. Your pathology report - tumor grade, stage, lymph node involvement, margins, lymphovascular invasion
2. Imaging findings - extent of disease, resectability assessment
3. Biomarker results - which determine treatment eligibility
4. Treatment options - surgery timing, chemotherapy regimens, targeted therapy, immunotherapy
5. Clinical trial opportunities - whether you might qualify for research studies
6. Coordination of care - ensuring all specialists are aligned on the plan

How to Request Tumor Board Review

Ask your oncologist directly: "Can my case be presented to the multidisciplinary tumor board?" Most cancer centers have formal processes for this, and many present cases routinely.

What to mention:

• Your diagnosis and stage
• Any complex features (metastatic disease, locally advanced cancer, specific mutations)
• Whether you want to explore all available options including clinical trials

Key Questions to Ask Your Team

1. "Will my case be reviewed by a multidisciplinary tumor board?"
2. "What biomarker testing has been done, and how does it affect my treatment options?"
3. "Are there any clinical trials I might be eligible for?"
4. "What is the recommended treatment plan, and why?"
5. "If I don't respond to initial treatment, what are the next steps?"

---

Important Context from NCCN Guidelines

The NCCN Guidelines emphasize that treatment decisions depend heavily on:

• Stage of disease (stages I-IV)
• MSI/MMR status (determines immunotherapy eligibility)
• Specific mutations (KRAS, NRAS, BRAF, HER2)
• Resectability (whether surgery can remove all disease)

These factors mean your individual case may require specialized expertise from multiple specialists to determine the optimal approach.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.